Stefania Crucitta

Dr. Stefania Crucitta


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
ARAlessandra Romandini
Alessandra Romandini
CRChiara Resnati
Chiara Resnati
SCStefania Crucitta
Stefania Crucitta
Stefano AgliardiStefano Agliardi
Stefano Agliardi
FDFederico D'Amico
Federico D'Amico
CGCostantino De Giacomo
Costantino De Giacomo
The rise of multidrug-resistant (MDR) pathogens in the pediatric population represents a significant global health challenge, compounded by a historically stagnant antibiotic pipeline for children. While several novel antibiotics have been approved for adults in recent decades, pediatric labeling is often deferred due to the complexities of developmental pharmacology and due to a certain precautionary prudence in introducing new drugs onto the market for this population. This review explores the landscape of the most recent antibiotics, including advanced cephalosporins (ceftaroline, cefiderocol, and ceftobiprole), novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime/avibactam, meropenem/vaborbactam), and long-acting lipoglycopeptides. We analyze their approval trials, pediatric-specific PK/PD profiles, and the balance between on-label use and evidence-based off-label prescriptions. Furthermore, we emphasize the role of antimicrobial stewardship through the “3 D’s” rule and the evolution of Therapeutic Drug Monitoring (TDM) from reactive safety controls to proactive, model-informed precision dosing (MIPD). Finally, we advocate for a multidisciplinary synergy between pediatricians and pharmacologists as the cornerstone for optimizing outcomes and preserving the efficacy of the future antibiotic pipeline.

30 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ARAlessandra Romandini
Alessandra Romandini
CRChiara Resnati
Chiara Resnati
SCStefania Crucitta
Stefania Crucitta
Stefano AgliardiStefano Agliardi
Stefano Agliardi
FDFederico D’Amico
Federico D’Amico
CGCostantino De Giacomo
Costantino De Giacomo
The rise of multi-drug resistant (MDR) pathogens in the pediatric population represents a significant global health challenge, compounded by a historically stagnant antibiotic pipeline for children. While several novel antibiotics have been approved for adults in recent decades, pediatric labeling often lags due to the complexities of developmental pharmacology and to a certain precautionary prudence in introducing new drugs onto the market for this population. This review explores the landscape of "new" antibiotics, including advanced cephalosporins (ceftaroline, cefiderocol, ceftobiprole), novel beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftazidime/avibactam, meropenem/vaborbactam), and long-acting glycopeptides. We analyze their approval trials, pediatric-specific PK/PD profiles, and the balance between on-label use and evidence-based off-label prescriptions. Furthermore, we emphasize the role of Antimicrobial Stewardship through the "3 Ds" rule and the evolution of Therapeutic Drug Monitoring (TDM) from reactive safety checks to proactive, Model-Informed Precision Dosing (MIPD). Finally, we advocate for a multidisciplinary synergy between pediatricians and pharmacologists as the cornerstone for optimizing outcomes and preserving the efficacy of the future antibiotic pipeline.